Genetics and Therapies for GM2 Gangliosidosis. by Cachon-Gonzalez, Begona et al.
1 
 
Genetics and Therapies for GM2 Gangliosidosis  
*María Begoña Cachón-González1, Eva Zaccariotto1 and Timothy Martin Cox1 
1Department of Medicine, University of Cambridge, Cambridge, UK 
 
* Address correspondence to this author at Department of Medicine, University of Cambridge, Level 5, 
PO Box 157, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK; Tel: +44 1223-336859;   Fax: 
+44 1223-336846; Email: mcb23@medschl.cam.ac.uk 
 
ABSTRACT 
Tay-Sachs disease, caused by impaired β-N-acetylhexosaminidase activity, was the first GM2 gangliosidosis to 
be studied and one of the most severe and earliest lysosomal diseases to be described. The condition, associated 
with the pathological build-up of GM2 ganglioside, has acquired almost iconic status and serves as a paradigm 
in the study of lysosomal storage diseases.  Inherited as a classical autosomal recessive disorder, this global 
disease of the nervous system induces developmental arrest with regression of attained milestones; 
neurodegeneration progresses rapidly to cause premature death in young children. There is no effective 
treatment beyond palliative care, and while the genetic basis of GM2 gangliosidosis is well established, the 
molecular and cellular events, from disease-causing mutations and glycosphingolipid storage to disease 
manifestations, remain to be fully delineated. Several therapeutic approaches has been attempted in patients, 
including enzymatic augmentation, bone marrow transplantation, enzyme enhancement, and substrate reduction 
therapy. Hitherto, none of these stratagems has materially altered the course of the disease. Authentic animal 
models of GM2 gangliodidosis have facilitated in-depth evaluation of innovative applications such as gene 
transfer, which in contrast to other interventions, shows great promise. This review outlines current knowledge 
pertaining the pathobiology as well as potential innovative treatments for the GM2 gangliosidoses. 
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INTRODUCTION 
The GM2 (monosialoganglioside2) gangliosidoses are caused by mutations in the α- and β-subunits of 
β-hexosaminidase (EC 3.2.1.52), named Tay-Sachs disease (TSD; OMIM 272800) and Sandhoff-Jatzkewitz 
disease (or Sandhoff disease, SD; OMIM 268800) respectively, and mutations in the GM2 activator protein, 
GM2 activator protein deficiency (OMIM 272750). These are emblematic neuronopathic lysosomal storage 
diseases (LSDs), that are relentlessly fatal and clinically indistinguishable but for subtle visceral and skeletal 
features in SD. Based on the time of onset, these diseases are often classified into infantile, juvenile and adult 
forms. Broadly speaking, the acuteness and severity of the disease hinges on the activity of the residual enzyme. 
The GM2 gangliosidoses have in common the inability to degrade GM2 ganglioside, an intermediate 
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sphingolipid in the synthesis and degradation of higher brain gangliosides, which, being particularly abundant  
in the nervous system, can accumulate in large quantities. Tay-Sachs and Sandhoff-Jatzkewitz disease bear the 
eponyms of the physicians/scientists who first described/reported them. 
 
FIRST DESCRIPTIONS 
The British ophthalmologist Waren Tay, Assistant Surgeon to the London hospital, Whitechapel and 
working at several hospitals in East London in the late 19th century carried out an examination of the eye in a 
one-year-old infant who suffered from weakness in the neck and limbs. Using the primitive ophthalmoscopes of 
the day, he found an unusual discoloration of the maculae, now known as "cherry-red spot". The child died six 
months after Tay’s first examination and he reported the case in 1881[1]; unfortunately, a post-mortem 
examination was unavailing as to the cause of the neurological disease. In 1884, Tay described further children, 
similarly affected in the same family. Noting the clustering of this disease in families, Tay considered this to be 
a congenital disorder. 
Bernard Sachs, a neurologist in New York City, unaware of Tay’s reports, published in 1896 a 
description of a disorder in infants with characteristics strikingly similar to those reported by Tay - the familial 
nature of the condition, early blindness, arrest of cognitive development, progressive weakness, and death in 
early childhood - and gave it the name "amaurotic familial idiocy" [2]. The following year, having studied 
several post-mortem samples, Sachs provided a description of the cardinal neuropathological features of the 
disease, namely, the grossly enlarged nature of most neurones in the brain, which contained a “detritus-like 
mass”, realising that this appearance represented a pathognomic manifestation of the disease [3]. Later, based on 
descriptions from the medical literature of more than 130 affected children Slome proposed the inheritance of 
the disease to be autosomal recessive [4]. 
 
NATURE AND LOCATION OF THE STORAGE MATERIAL 
The composition of the major lipids accumulating in TSD was elucidated by the German biochemist, 
Ernst Klenk in the 1940s:  Klenk coined the term ganglioside for the previously unknown group of neuraminic 
acid-containing glycosphingolipids (GSLs) that are abundant in ganglion cells. The saccharide and sialic acid 
sequences in the principal ganglioside in TSD, GM2, was deduced by Svennerholm [5], and its exact structure 
elucidated by Makita and Yamakawa in the early 1960s [6]. 
The introduction of electron microscopy revolutionised morphological evaluation of cellular structure. It 
allowed for the first time, visualisation of the characteristic "membranous cytoplasmic bodies" (MCBs) in the 
neurones of post-mortem brain tissue from a patient with Tay-Sachs disease [7] [8], and revealed in florid detail 
the “detritus-like mass” to which Sachs had alluded as the pathological hallmark of the disease. Correy and 
Terry also showed that these bodies could be partially purified by centrifugation and the fractions enriched for 
MCBs contained abundant GM2 ganglioside. 
It is notable that Christian de Duve and colleagues in the 1950’s had adopted an independent and entirely 
distinct approach to the exploration of cellular structure and function - in effect using the centrifuge ultimately 
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to characterize the biochemical properties of what he designated subcellular “lysosomal particles” by means of 
tissue fractionation. De Duve discovered that acid phosphatase and other hydrolases co-sedimented with these 
dense components (or, as termed later, organelles). While these sedimentable enzyme activities catalysed the 
hydrolysis of many diverse substrates, it was noted that all possessed a pH optimum in the range 4 -5.5 - 
immediately suggesting a digestive function for the newly identified particles [9].  With the introduction of lead 
phosphate and other substrates yielding electron-dense products of the phosphatase reaction before fixation and 
electron microscopy, it was possible to demonstrate acid phosphatase activity in  MCBs, thus indicating their 
lysosomal nature [10] [11].  Brady proposed a catalytic impairment in the hydrolysis of the terminal sugar [N-
acetylglactosamine] in the accumulating GM2 ganglioside as the biochemical defect in TSD, resembling 
enzymatic defects already identified in related diseases such as Gaucher and Niemann-Pick diseases [11].  
Early descriptions of the lysosome as the digestive machinery of the cell still stand, but in its brief 
history, our view of this organelle has undergone an extraordinary evolution. Beyond its catalytic properties, the 
lysosome is central for autophagy (a term coined by de Duve) to be taken to completion, and participates in 
plasma membrane repair, endocytosis and exocytosis, energy metabolism and signalling. In particular cells, 
certain lysosome-related organelles, such as the melanosome and platelet granules are able to carry out 
specialised functions. Externalised lysosomal enzyme undergoing bulk release into the fluid phase of sub-
osteoclastic space or immune synapse generated by NK lymphocytes carry out other essential but highly 
differentiated functions. Moreover, lysosomal biogenesis and function is exquisitely regulated, with 
transcription factor EB (TFEB) as the master regulator; not only does TFEB regulate the lysosome but also 
controls autophagy [12]. Transcription factor EB orchestrates the co-expression of genes encoding lysosomal 
proteins as a response to specific cellular cues. TFEB translocates to the nucleus, where it activates transcription 
of its target genes in what appears to be an adaptive response to the presence of stored metabolites, in cells from 
patients with lysosomal storage diseases; remarkably, under normal conditions, TFEB does not drive basal 
transcription of its targets [13]. 
 
FUNCTION OF GLYCOSPHINGOLIPIDS 
Glycosphingolipids (GSLs) are a large family of complex molecules comprising many thousands of 
biological variants which localize primarily to the plasma membrane, but they are also components of several 
cellular organelles and the nuclear membrane [14]. At the cell surface, glycosphingoplipids cluster in 
microdomains [15, 16], with functions involved in cell-cell recognition [17], signal transduction [18, 19], and 
internalization of cargo [20], to name but a few. As inferred from their qualitative and quantitative patterns of 
expression, it is now clear that GSLs participate in dynamic neurodevelopmental processes [21], including 
neuritogenesis, axonogenesis, and synaptogenesis [22-25]. Glycosphingolipids show striking molecular 
diversity as expected for complex biological molecules, implicated in a multiplicity of functions, including 
provision of the water-barrier layer in the skin of all land-based vertebrates; but the extent of their rôle in nature 
remains to be fully characterized. This represents a considerable challenge, partly due to the large number of 
GSLs, their heterogeneity and interrelationships [26]. Experiments employing genetic engineering to disrupt 
specific pathways of GSL biosynthesis in mice and the subsequent analysis of the resulting phenotype has 
unveiled some of their key biological functions.  
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The GM2/GD2 synthase (β -1, 4-N –acetylgalactosaminyl transferase), encoded by B4galnt1, transfers 
N-acetylgalactosamine to lactosylceramide, and initiates the synthesis of the ganglio-series sphingolipids, 
including the sialic acid-containing gangliosides [27]. Two groups working independently, created mice with 
deletions in B4galnt1, and, as expected, B4galnt1-/- mice lacked complex gangliosides, and instead expressed 
GM3 and GD3 [28, 29]. Unexpectedly, brain development in B4galnt1−/−  mice was not compromised. 
However, analysis of the two animal models led to different interpretations:  Takamiya and co-workers 
described their mouse model as having subtle neurological dysfunction at birth, with neurodegeneration only 
developing with age. In contrast, those mice reported by Sheikh and colleagues suffered dysmyelination of 
central axons and demyelination of peripheral nerves, leading to axonal degeneration and impairment of motor 
function. Axonal membrane gangliosides are thought to act as ligands for the oligodendrocyte protein MAG 
(myelin associated glycoprotein), which favours axon-glia interactions [30]. This idea is suggested by the 
finding that B4Galnt1−/− mice have diminished MAG expression in their brain and conversely, MAG-deficient 
mice develop a phenotype resembling B4Galnt1 −/− [31]. Overall, the experimental results obtained in these 
experimental mice support the view that complex gangliosides are essential for myelin function and stability 
[32]. 
 
ELEMENTS OF THE β-HEXOSAMINIDASE SYSTEM 
A seminal finding by Robinson and Stirling in 1967 revealed the existence of two forms of N-acetyl-β-
glucosaminidase, which could be resolved by starch gel electrophoresis and later separated by chromatography 
on DEAE-cellulose, an acidic form A and a basic form B. In agreement with de Duve’s findings, both isoforms 
of the enzyme, now known as ß-hexosaminidase, are localised to the lysosomal fraction [33]. Using similar 
analytical methods, Okada and O’Brien showed that leukocytes from patients with Tay-Sachs disease lacked the 
activity of the A isoform, while heterozygotes had reduced activity, consistent with the expected gene dosage 
effect for a simple Mendelian autosomal recessive trait [34]. This discovery had important implications for 
families afflicted by the disease, through targeted screening programmes in the at-risk Ashkenazi community at 
large and, subsequently, for clinical diagnosis. Prenatal diagnosis of fetal TSD from amniotic cells, and carrier 
status for individuals wishing to be tested was soon introduced, so that within two years, community education 
and screening programs were made widely available. These programmes, pioneered by Michael Kaback, have 
been critical for reducing the incidence of the disease principally in Jews, in whom the carrier frequency of 1 in 
27 individuals predicts a natural incidence of ≈ 1 in 2900 births – now a greater than 90% reduction has been 
reported for the USA, and has been emulated in many other countries [35, 36]. 
Sandhoff and colleagues were puzzled to examine material from an infant with severe neurodegeneration 
and GM2 gangliosidosis but with a total absence of both forms of β-hexosaminidase in brain tissue; in contrast, 
ß-hexosaminidase activity in tissues from TSD patients show an increase in total β-hexosaminidase activity 
[37]. This disorder is now known as Sandhoff-Jatzkewitz disease. The explanation for these unexpected 
enzymological findings emerged from the studies by Srivastava and Beutler, who employed immunochemical 
techniques to distinguish between the A and B forms and concluded that the two isoforms of β-hexosaminidase 
share a common subunit, Hex A being a heteropolymer (αβ)n and Hex B a homopolymer (ββ)n [38]. The model 
also predicted the existence of a Hex S isozyme, a homopolymer of the α subunit (αα)n. If correct, the absence 
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of subunit β would obliterate the activity of Hex A and Hex B, whereas if subunit α was missing, Hex A and 
Hex S activities would be deficient. The model of Srivastava and Beutler was subsequently verified by 
insightful hybridization and cell fusion experiments in which TSD and SD fibroblasts were able mutually to 
complement each other, resulting in the formation of Hex A [39], later supported by mapping of Hex A and Hex 
B expression to chromosomes 15 and 5 respectively [40]. Additional complexities of the β-hexosaminidase 
system emerged some years later when Conzelmann and Sandhoff identified another exceptional infant with 
GM2 gangliosidosis who was found to have activities of Hex A and Hex B within the healthy reference range 
when assayed in the presence of artificial substrates.  Detailed investigations, including the use of the natural 
substrate, GM2 ganglioside, led to the discovery of a specific activating factor, later shown to be a small protein 
that is specifically required for the lysosomal breakdown of GM2 ganglioside. The existence of this activator 
protein accounts for the apparently normal activities of both β-hexosaminidase isozymes often reported in these 
very rare cases of GM2 gangliosidosis [41] (Fig. 1).  
 
β-HEXOSAMINIDASE BIOSYNTHESIS AND UPTAKE 
  Experiments in the laboratory of Elizabeth Neufeld elegantly allowed elucidation of the β-
hexosaminidase biosynthesis pathway. D’Azzo and colleagues investigated the cell biology of β-
hexosaminidases by means of radiolabelled pulse-chase studies using 32P-labelled inorganic phosphate and [3H]- 
L-Leucine  in fibroblasts cultured from healthy subjects and patients with GM2 gangliosidosis; 
immunoprecipitation with antisera specific for the Hex isozymes and their subunits permited the molecular 
forms of the proteins to be followed during biosynthesis. Their discovery, “that proteins destined for the 
lysosome undergo modifications on the way to and at their final destination in the lysosome”, was of great 
significance. They described the principal steps of this process as: (1) β-hexosaminidase isozymes first appear in 
a precursor form; (2) mannose 6-phosphate (M6P) motifs are attached to these precursors, and ( 3) after 
traversing the Golgi and on reaching the lysosome, the precursors are converted into mature forms of smaller 
molecular mass [42, 43]. Previous studies from the laboratories of William Sly, Stuart Kornfeld and Elizabeth 
Neufeld had shown that the M6Ps are recognition tags necessary for correct targeting of nascent proteins to the 
lysosome. 
Experimental evidence indicates that in the complex case of heterodimeric Hex A, subunits α and β are 
synthesised independently and when in the endoplasmic reticulum (ER): 1) they lose their signal peptide; 2) 
acquire N-linked oligosaccharides and intra-chain disulphide bonds; and 3) M6P moieties are attached. It is only 
after the acquisition of the M6P tags that α and β subunits associate in the ER. It is believed that in a step 
facilitated by M6P receptors, the precursor isozymes travel through the Golgi. They reach the lysosomes 
through intermediate acidified compartments where the enzyme dissociates from the receptors - presumably, 
allowing the receptors to recycle back to the Golgi for further use. As with other soluble acid hydrolases 
destined for the lysosome, a significant fraction (≈ 20%) of the M6P-tagged protein is secreted into the 
extracellular space and can be detected in the medium of cultured cells. The secreted enzymes are catabolically 
active and able to re-enter the secreting and indeed neighbouring cells - a process of secretion-recapture that 
allows mutual cross-correction of lysosomal enzyme deficiencies in cultured cells. The ability to supply 
exogenous glycoproteins that are appropriately decorated with mannose 6-phosphate and other moieties for 
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delivery to the lysosome is a phenomenon of great importance for therapeutic exploitation in lysosomal diseases 
(Fig. 1). Binding and internalization is mediated largely through M6P receptors present on the cell surface; the 
protein cargo eventually reaches the lysosome after intracellular trafficking through intermediate compartments 
in the endosomal-lysosomal pathway. Of note, based on their biosynthetic labelling studies, D’Azzo and 
colleagues were of the view that association with beta-chains is necessary not only for acquisition of catalytic 
activity but also for transport of alpha-chains to lysosomes. The proteolytic cleavage sites in the 
hexosaminidases and resulting processed products were identified after the amino acid sequences of the subunits 
could be inferred from characterization of their cDNAs [44-47]. It transpires that proteolytic cleavage of the 
assembled β-hexosaminidase subunits (which remain associated by disulphide bonds after processing) is not 
necessary for their enzymatic activity [48, 49]. 
 
CHARACTERIZATION OF HEXA, HEXB, AND GM2AP 
Cloning of the β-hexosaminidase genes encoding α- (HEXA) and β-subunit (HEXB), and the GM2 
activator protein (GM2AP) required considerable effort, partly because of the low abundance of their mRNAs. 
Myerowitz and Proia isolated the first α-subunit cDNA clone in 1984 [50], and using a different approach 
Korneluk and colleagues published similar results a year later [51]. Two α-subunit mRNA species of 2.1 kb and 
2.6 kb were identified; importantly, these were not detectable in fibroblasts obtained from patients with classical 
infantile Tay-Sachs disease [52]. The total coding sequence, which includes a 22-amino acid signal peptide at 
the N-terminus, consists of 528 amino acids; and the genomic structure, scattered over a 35 kb sequence on 
chromosome 15q24.2, comprises 14 exons [53]. O’Dowd and co-workers detected a β-subunit mRNA of 2.2 kb, 
absent in cells obtained from a child with Sandhoff diease [54]. Information provided by the O’Dowd’s paper 
allowed Proia and colleagues to isolate a 1.7 kb cDNA from liver. The total β-subunit coding sequence consists 
of 556 amino acids, with a 42-amino acid signal peptide at the N-terminus. Of note, HEXB also consists of 14 
exons distributed over a 40 kb sequence localised to chromosome 5q12. Moreover, the intron/exon boundaries 
are conserved between the two genes in 12 out of 13 introns [55]. Korneluk aligned the primary sequence of 
pre-α and pre-β polypeptides, revealing 55% and 57% similarity in the nucleotide and amino acid sequences, 
respectively. This level of sequence similarity suggested a common ancestral gene for the two subunits [56].  
Schröder and colleagues succeeded in cloning the GM2 activator protein gene (GM2A), consisting of 4 
exons and 3 introns spread across a 16 kb sequence [57]; this maps to human chromosome 5q31.2. 
In spite of the similarities between subunits α and β, functionally different active sites permit the multi-
isozyme system to hydrolyse diverse substrates containing β-linked N-acetylhexosaminyl residues. The active 
sites of both subunits, in dimeric form, are able to hydrolyse many of the same neutral natural and artificial 
substrates - oligosaccharide moieties from proteins and neutral glycolipids, as well as from certain 
mucopolysaccharides - showing redundancy in the system. In contrast, it is the catalytic site in subunit α that 
hydrolyses negatively charged substrates. Degradation of GM2 ganglioside can only be attained by 
heterodimeric Hex A in vivo. In association with the GM2 activator protein, Hex A is specifically required to 
catalyse removal of the terminal non-reducing N-acetylgalactosamine residue from GM2 ganglioside - the 
activator protein serves as a lipid transporter that interacts with both the carbohydrate and lipid portions of the 
ganglioside and presents it to Hex A for hydrolysis [58-61]. The crystallographic structures of Hex A [62], Hex 
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B [63], and GM2 activator protein [64] provide useful fine detail about the effects of pathogenic mutations in 
these proteins and the mechanisms of catalysis. Structural analysis moreover suggests that dimerization is 
essential for activity in each subunit and is consistent with the lack hitherto of any evidence that monomeric 
subunits possess enzymatic activity. [65]. Characterization of the HEXA, HEXB and GM2A genes enabled 
identification of the molecular defects that cause GM2 gangliosidosis. These advances in molecular genetics 
also definitively confirmed that while mutations in the α- and β-subunit genes cause TSD (B variant) and SD (0 
variant) respectively, defects in the GM2 activator protein cause the so-called AB variant form of GM2 
gangliosidosis  [66, 67] (Fig. 1). Consequently, personalised medicine for disease diagnosis and genetic 
counselling is now possible because disease-causing mutations can be pinpointed with precision and, in a few 
cases, the clinical phenotype predicted. 
 
HETEROGENEITY OF THE DISEASE 
For historical reasons, when Sachs first came across TSD, the catchment area of his patients in New 
York City included many Jewish families of Eastern European ancestry, and he logically concluded TSD to be a 
Jewish disease. However, we now know the disease is panethnic, including blacks [68] and Asians [69]. 
Moreover, contrary to early indications that TSD is a disease due to a single cause, with the advent of DNA 
sequencing, it became clear that numerous mutations cause infantile disease. An early example came from 
mutation analysis carried out in French Canadians and Ashkenazi Jews, against all preconceptions the disease 
was due to distinct mutations in the two populations [70]. Unexpectedly, TSD within Ashkenazi Jews can also 
be caused by several mutations [71]; seven HEXA mutations have been found in Moroccan Jews with Tay-Sachs 
disease, a Sephardic group - five mutations are apparently exclusive to the Moroccans but two also occur in the 
Ashkenazim [72]. 
Carrier frequency can vary greatly between different populations; for example, TSD is estimated at 1 in 
14, 1 in 30 and 1 in 300 for Eastern Quebecois in Canada, Ashkenazi Jews and the ‘general’ population, 
respectively [73, 66]. These early revelations pointed to the existence of different mutations being responsible 
for the same disease, which paralleled findings in other genetic disorders. Similarly, SD is no respecter of ethnic 
group [74-76], and the number of mutations in subunit β are numerous and distributed widely over the entire 
gene [77]. 
Over 100 distinct mutations have been reported for HEXA alone [78] (see also an online database at 
www .hexdb.mcgill.ca), which include deletions, splicing aberrations, nonsense and missense mutations; leading 
to deficiencies in transcription, translation, inappropriate protein folding and/or dimerization and catalytic 
dysfunction [79]. The most common and severe forms of GM2 gangliosidosis are often found to have a 
complete deficiency in Hex A activity. While total Hex activity is close to normal in TSD - attributable to active 
Hex B - only 2-4% of normal total Hex activity is detectable in SD, despite normal amounts of α-subunit 
mRNA. Low affinity of the α-subunits for each other explains the detectable but small quantities of Hex S. The 
less severe juvenile (subacute) and adult (chronic) onset forms are a consequence of mutations that allow for 
preservation of varying degrees of Hex A function, around 1-5% of normal, often the result of inadequate 
folding or dimerization. Most known missense mutations result in misfolded proteins; detected by the ER 
quality control system they are degraded by the ER-associated degradation pathway (ERAD), followed by 
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ubiquitination and removal by the proteasome [80-82]. Five to 10% of normal Hex A activity is estimated to be 
compatible with a disease-free life [79, 83]. In GM2A protein deficiency, Hex A and Hex B function is 
maintained against some substrates, but not against GM2 ganglioside - the critical threshold of normal 
hydrolysis being estimated at around 5-10% of normal activity, and disease manifestations are predicted to 
occur below this figure [84]. While these discussions provide guidance, caution is needed in relation to 
estimating true residual enzyme activities - especially using information obtained from assays conducted in 
diagnostic laboratories. In reality, determining the true activity of Hex A against its natural substrate GM2 
ganglioside (itself a biological substrate of chemical diversity owing to variation in sphingosine structures and 
acyl chain-lengths in the body) in lysosomes of nervous tissue in situ is extremely challenging. While substrates 
based on simple or more complex analogues of various composition can be used, in the past, the preferred 
solution has been to utilize radiolabelled natural GM2 ganglioside(s) – now prohibitively expensive and 
cumbersome to use.  
An intimate understanding of Hex A function, revealed by its crystal structure, was anticipated to 
facilitate prediction of disease phenotype for individual mutations. This expectation has not been fully realised; 
this is because spatial location of a mutation does not readily correlate with disease severity, except for those 
altering the active site. Moreover, many patients are compound heterozygotes, often harbouring a unique or 
unusual combination of mutations, and uncharacterized disease-modifying genes within families, together with 
epigenetic and environmental factors are suspected to influence the course of the disease. 
 
NATURAL HISTORY 
It is a remarkable fact that the prevalence of GM2 gangliosidosis in some at-risk populations is now 
lower than in the general population due to enzymatic and genetic screening. Although the authors are aware of 
tragic examples where targeted screening has failed, particularly in couples of mixed ancestry who request 
reassurance before planned pregnancies, community-based carrier screening and counselling in traditional at-
risk communities of high endogamy has been extraordinarily effective. [85, 86]. Reported estimates of the 
incidence of TSD and SD in the population at large are 1 in 222,000 and 1 in 422,000 live births, respectively 
[87]. 
A few recent studies have formally reviewed survival and rate of functional decline in GM2 
gangliosidosis. The study by Bley and colleagues focused on the infantile forms of TSD and SD. It included 
data from patient surveys (TSD, n= 72; SD, n= 20) recruited by the National Tay Sachs & Allied Diseases 
Association (NTSAD), NTSAD retrospective database (n= 103) in the USA, and literature reports (n= 121). 
Most infants were of mixed ethnic origin, Jewish or unknown. Diagnosis of disease was at a mean of just over 
one year of age, and the most common initial symptoms were developmental arrest (83%), abnormal startle 
response (65%), and reduced muscle tone (60%). Seizures were common and particularly prominent during the 
late stages of the disease. Importantly, early development appeared to progress normally in most cases - 
supporting the generally held notion that developmental arrest, and not delay, is more typical of infantile GM2 
gangliosidosis. About half these patients died by the age of 3½ years [88]. 
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Maegawa and colleagues reported on 21 new patients with juvenile/subacute GM2 gangliosidosis: of 
these, 13 were from Canada and 8 from Brazil (TSD, n= 15; SD, n= 6) representing 15 unrelated families of 
diverse ethnicity. Among the 15 patients with TSD and 6 with SD, respectively 11 and 5 different mutations 
were identified. The mean age of onset (first symptom) was 5.3 ± 4.1 years (range: 1.5–15 years). About half 
these patients died in the first decade of life, and only 25% survived to their late teens. Disease manifestations in 
this group of patients are more variable than in the acute infantile form, but gait and speech difficulties were 
experienced by all patients as the disease progressed, impaired coordination (95%) and cognitive impairment 
(80%) were almost invariable; psychiatric disturbances were noted in two patients. Cerebellar atrophy, followed 
by generalized cerebral atrophy was the most common neuro-radiological finding. Very similar trends resulted 
from the analysis of a group of 134 patients previously reported in the literature (1968-2006) (TSD, n= 96; SD, 
n= 27) [89]. Differences in symptoms between TSD and SD patients were also apparent; for example, sleep 
problems, muscle wasting, and diarrhoea/constipation were more prevalent in SD suggestive of autonomic 
neuropathy. 
Smith et al. studied 73 cases of GM2 gangliosidosis in the UK (TSD, n= 40; SD, n= 31; GM2AP 
deficiency, n= 2) during the period 1997-2010, using data provided by the British Paediatric Surveillance Unit. 
The GM2 gangliosidoses represented 6% (73⁄1164) of all diagnosed cases of progressive intellectual and 
neurological deterioration. Most (85%) were sporadic cases with no family history but notably, children of 
Pakistani ancestry predominated, in particular the juvenile form of SD (10/11). As with other populations, 
infantile forms predominated (75%). The mean age at symptom onset was 6.2 and 4.7 months for infantile TSD 
and SD, respectively, and 26.2 and 34.7 months for the corresponding juvenile variants. As with the earlier 
findings by Bley and colleagues, the mean survival for the infantile forms was about 3 years, the clinical 
manifestations were not appreciably different from those reported in the literature [90]. 
Markedly attenuated late-onset forms of Tay-Sachs and Sandhoff diseases have been increasingly 
recognised. Although initially first reported as Late-onset Tay-Sachs disease (LOTS) principally in Ashkenazi 
Jews - associated with homozygosity for the missense HEXA mutation, G269S - both subtypes of GM2 
gangliosidosis may cause late-onset disease. Presentation is highly variable and the disease is frequently 
mistaken for other well-known neurodegenerative disorders such as amyotrophic lateral sclerosis (motor 
neurone disease) and cerebellar ataxia; peripheral neuropathy may be a presenting feature –especially in 
Sandhoff disease. Common presenting symptoms include clumsiness and ataxia combined with leg muscle 
weakness with onset in the late adolescent period. Cognitive ability is often long-preserved allowing retention of 
employment, but up to 40% of patients develop psychiatric manifestations including bipolar disorder or 
psychosis. It is unclear whether this form of disease shortens life, but most affected patients at least lose their 
physical independence, require assisted ambulation and support [91]. 
With several new treatments on the horizon for the GM2 gangliosidoses, accurate description of clinical 
manifestations to chart the natural history of the disease and validated disease severity scores, will be important 
for the evaluation of potential therapeutic efficacy and in the development of inclusion/exclusion criteria in 
clinical trials. Given the relentless nature of the disease early therapeutic intervention will be of the essence for 
optimal outcomes. Moreover, early diagnosis facilitates management of the condition and increases awareness 
in affected families and at-risk relatives, making informed reproductive choices possible. 
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DIAGNOSIS 
GM2 gangliosidosis in an infant with a neurodegenerative disease is usually characterized by 
developmental arrest and features indicating combined cerebral and cerebellar disease (poor axial tone with 
progressive limb spasticity and is typically raised by certain clinical signs such as poor visual fixation and a 
prominent startle reflex. The presence of perifoveal pallor and the cherry-red or pigmented macular spot is not 
completely specific but is a near-pathognomic sign of this disease. 
 In suspected cases, the mainstay of diagnosis relies on enzymatic assay of β-hexosaminidase activities, 
usually carried out in plasma and/or peripheral blood white cells using two fluorogenic artificial substrates - 
MUG (4-methylumbelliferyl-beta-D-N-acetylglucosamine) and its sulphated congener, MUGS (4-
methylumbelliferyl-beta-D-N-acetylglucosamine-6-sulphate)]. The latter preferentially hydrolysed by Hex A 
and Hex S. Fibroblast lysates or extracts of other tissues can also be used but in most cases the reference 
parameters for healthy subjects are less statistically robust. Assay of control lysosomal enzyme activities should 
be determined in parallel. These studies should be conducted in an experienced biochemical genetics laboratory 
that has ideally been prepared for timely receipt of the samples. Enzymatic diagnosis is not fool-proof and for 
carrier detection, as well as rigorous diagnosis of disease, molecular analysis of the HEXA and HEXB genes is 
increasingly carried out in addition. This is to avoid discrepancies arising from artefacts and the presence of 
pseudodeficiency alleles or mutations such as R288H in HEXA  that lead to a modest or undetectable deficiency 
of enzyme activity with the artificial substrates but a Hex A enzyme that fails to be  activated by the GM2 
activator protein. Molecular analysis of the GM2A gene is necessary for diagnosis of the cognate activator 
deficiency [92]. 
 
ANIMAL MODELS 
Studies of GM2 gangliosidosis using cell lines or primary cells in culture have been instrumental in our 
understanding of the biology underlying GM2 gangliosidosis, and have played a key rôle in mechanistic 
understanding. However, to study pathogenesis and test prospective therapies, authentic animal models of 
disease are highly desirable. Naturally occurring as well as genetically engineered animal models are available 
for experimentation. Mutations in hexb have been identified in several breeds of cats [93], and in hexa in sheep 
[94], dogs [95, 96] and flamingos [97]. Clearly, among these models of disease, some are more amenable to a 
research setting, and we refer the reader to the excellent review by Lawson and Martin on the utility of these 
animals [98]. 
In the 1990s, two groups working independently, the laboratory of Proia [99] and that of Gravel [100], 
generated mouse strains with disrupted hexa and hexb genes as models of TSD and SD, respectively. To their 
surprise, the TSD mice did not mimic human infantile TSD, and although the animals showed some storage of 
GM2 ganglioside, clinical manifestations were not immediately apparent. In contrast, SD mice developed a fatal 
neurodegenerative disease and died at age 4-5 months. These investigators reasoned that the mild disease in 
TSD mice could be explained by the existence of a biochemical bypass mediated by a sialidase, now considered 
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to be Neu3 [101] which if conserved in humans fails to function effectively. Mouse and cat models of the GM2 
protein activator deficiency are also available [102, 103]. 
As illustrated by the disparate phenotypes between murine and human TSD, species-specific differences 
may exist, and interpretation of results from animal models should be taken with caution when extrapolating to 
human disease. Nevertheless, these animal models are powerful research tools and their importance cannot be 
overestimated for translational studies. The advantages of using mouse models of disease for testing novel 
therapies are: 1) readouts of successful or failed approaches are relatively rapid; 2) large numbers of animals 
are produced in a short time, which are easily housed in a small animal facility; and 3) high throughput 
analysis of tissue is of a manageable scale for small laboratories. However, the mouse brain is small, about 
1/1000 that of a human infant, making accurate injections of small structures difficult, but those of the cat and 
sheep better approximate to the infant human brain in complexity, organization, and size (1/10 and 1/3 
respectively). Cat and sheep are long-lived animals and well suited for surgical interventions and clinical 
evaluation over many years [98]. Nevertheless, there are disadvantages associated with the use of large animal 
models. These include: 1) difficult ethical justification associated with the experimental use of more sentient 
animals - particularly for early evaluation of novel therapies; 2) high maintenance cost; 3) specialist care by 
highly qualified veterinarians; 4) time required to generate animals numbers to achieve meaningful statistical 
power; and 5) the large volumes of tissue that is required for analysis and to obtain a systematic and thorough 
investigation of interventional outcomes. 
 
PATHOLOGY 
There are few reports in the literature on the histopathological features of human GM2 gangliosidosis 
that are more comprehensive than those by Aronson, on his observations of infantile TSD. He found that at 
autopsy, the brains were heavier than normal, probably due to gliosis; but in contrast to the obvious microscopic 
abnormalities, they showed no gross pathological features macroscopically, except for oversimplification of 
surface fissures and broadened sulci. Neuronal depletion was only prominent in the cerebral cortex, and 
demyelination in the cerebral white matter. Aronson considered that arrest and inhibition of myelin formation 
rather than loss of existing myelin was most likely, because no evidence of recent myelin breakdown was 
apparent; however, numerous activated microglia and changes of mild astrogliosis were present in areas of grey 
matter. All levels of the neuraxis showed the characteristic neuronal alterations and gliosis and, in addition, 
endothelial cells were distended with pathological lipid. Aronson was struck by the abrupt onset of the illness 
and despite the severe neuropathological destruction, the degree of function remaining until late in the course of 
the disease, when a threshold appears to be reached and normal neurodevelopment stops [104, 105]. 
It remains a matter of intense debate, which changes represent the primary expression of the 
neuropathology and which are, in effect, secondary changes consequential on the original defect. While the 
accumulation of gangliosides is generally seen as the primary insult to neurons, demyelination and inflammation 
for example are often considered a mere consequence of neuronal deterioration. However, this has been strongly 
contested, and there is evidence to suggest that both, demyelination and inflammation, actively participate in the 
disease process and its destructive effects on neurological function. Despite more than a century of study, the 
path, from ganglioside accumulation to progressive neurodegeneration and death, is not yet fully characterized 
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or unravelled in molecular terms; better understanding of the cellular and molecular mechanisms of disease may 
still open up new possibilities for therapeutic intervention. 
 
Storage of GM2 ganglioside and related glycolipids 
The widespread presence of distended neurones containing numerous modified lysosomes - membranous 
cytoplasmic bodies - is the most conspicuous histological alteration in GM2 gangliosidosis. These bodies are in 
effect pathological lysosomes containing GM2 ganglioside and related glycosphingolipids, which can be 
detected immunohistochemically with monoclonal antibodies and gives a reaction for glycans with the periodic 
acid-Schiff reagent (Fig. 2).  
Pathological elements implicated in the disease process include:  
1) The presence of the unacylated metabolite lyso-GM2 (sialylgangliotriaosylsphingosine) in brain and 
plasma of patients and animal models of GM2 gangliosidosis – which has been presumed to have toxic 
properties when present in neural tissue [106, 107], and possibly resembling other pathological lysolipids, 
glucosylsphingosine in Gaucher’s disease [108, 109] or galactosylsphingosine in Krabbe disease [110]. 
2) Anti-ganglioside autoantibodies - linked to the more severe late stages of the disease [111]. 
3) There is evidence that accumulation of sphingolipids in the lysosomal compartment perturbs 
endosomal transport and sorting, disrupting cellular homeostasis [112]. 
4) Impaired autophagy - the overwhelming accumulation of storage material restricts the normal fusion 
between autophagosomes and lysosomes. One manifestation of this inhibition is the formation of inclusion 
bodies containing aggregates of polyubiquitinated proteins [113-116] and protein p62/SQSTM1, which targets 
ubiquitinated proteins to the autophagosome for degradation [117, 118]. Of note is the work of Micsenyi et al. 
on ceroid lipofuscinosis type 2 (CLN2), suggestive of lysosomal membrane permeability as the principle 
pathogenic event - rather than a compromised degradative mechanism - where the release of lysosomal contents 
into the cytosol stimulates the formation of p62-containing protein aggregates [119]. Displayed in figure 2 are 
hitherto unpublished data showing ubiquitin and p62 co-staining of neurones in murine SD (Fig. 2), which we 
take to signify the presence of dysfunctional autophagy and possibly increased lysosomal membrane 
permeability in experimental GM2 gangliosidosis. 
5) Progressive accumulation of α-synuclein - a protein naturally expressed in neurones and glia [120], 
which binds proteins [121] and lipid vesicles [122], and implicated in lipid metabolism [123]. Suzuki et al. 
demonstrated the presence of α-synuclein accumulation in human lipidoses [124] and in the brains of SD mice 
[125]. We also detected extensive α-synuclein aggregation in many areas of the brain and spinal cord of these 
mice; the protein is present in young SD animals and increases with age and disease severity [116]. The 
significance of this alteration as a contributing factor to disease progression and severity is unknown. However, 
Suzuki and colleagues showed that ablation of α-synuclein reduced the extent of the pathology but offered only 
minor neurological benefit in SD mice [126]. Clearance of α-synuclein relies on the ubiquitin-proteasome 
system [127] and the autophagy-lysosomal pathway [118], and when these pathways are dysfunctional, as it is 
the case for many neurodegenerative disorders, α-synuclein accumulates. It has been recently shown that 
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truncation of α-synuclein by the inflammasome protein caspase-1 causes its aggregation with concomitant 
neuronal toxicity [128]. Taken together, these findings suggest that the inflammasome and the 
proteasomal/autophagosomal/lysosomal systems are inextricably linked and interdependent. The studies also go 
a long way in showing how the pathological accumulation of cellular macromolecules has far-reaching 
consequences, revealed by the plethora of pathology and disease manifestations, particularly in those LSDs with 
neuronopathic features. 
In infantile cases of GM2 gangliosidosis most neurones are abnormal, but in later onset forms, 
particularly in adult patients, the visible abnormalities occur preferentially in particular anatomical sites. The 
result is a unique pattern and evolution of disease manifestations, which at first superficially may resemble other 
diseases and often lead to misdiagnosis [129-133]. 
 
Demyelination 
Haberland and colleagues studied the white matter of infantile GM2 gangliosidosis and found 
histological evidence of severe and extensive demyelination, and biochemically a decrease of 50-85% in 
cerebrosides. These investigators postulated that arrested myelinogenesis played a major part in the 
clinicopathological evolution of GM2 gangliosidosis and that secondary myelin loss was a contributing factor. 
They attributed the failure in myelination to interference with cerebroside synthesis [134]. Alterations in myelin 
composition in animal models of GM2 gangliosidosis have also been described [135, 136]. In line with these 
observations, when we examined the expression of oligodendrocyte-speciﬁc genes in the SD mouse, we found 
them reduced in all regions of the brain at an early age, both at the level of transcription and translation. 
Moreover, mRNA expression of uridine diphosphate (UDP)-galactose:ceramide transferase, the key enzyme in 
galactocerebroside biosynthesis, was down-regulated at all ages examined (5-19 weeks), and well before the 
onset of obvious disease signs [116]. Myelin deficits identified in the early stages of other LSDs, Nieman-Pick 
type A [137] and fucosidosis [138] for example, suggests that demyelination is likely to be a common feature in 
these disorders and central to their pathogenesis. 
 
Neuroinflammation 
The innate inflammatory response evolved to protect and minimise the effects of injury to the affected 
tissue, but when chronically stimulated, as in neurodegenerative diseases, expression of cytokines and pro-
apoptotic molecules results in an environment damaging to neurones, and a contributing factor to disease 
progression. 
Myerowitz et al. concluded, from expression analysis of cerebral cortex from patients with Tay-Sachs 
and Sandhoff disease, that inflammation is a factor that leads to neuronal cell death [139]. Moreover, in a 
previous histological and gene expression study of the SD mouse, these authors found that microglia activation 
and expansion preceded “massive neuronal death” [140]. Studies by others have confirmed some of these results 
[141] (Fig. 2). Inflammation is a consistent observation in all neurodegenerative disorders, regardless of the 
genetic defect, but it is difficult to prove unequivocally its contribution to disease progression and severity. The 
inflammatory response is a dynamic process, which involves numerous molecules, many of which have 
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overlapping functions. In an attempt to test experimentally the rôle of inflammation in GM2 gangliosidosis and 
anticipating an improved phenotype, several investigators have disrupted some of its elements, these include: 
ablation of cytokine expression - macrophage-inflammatory protein 1α (MIP-1α) [142], and tumour necrosis 
factor α (TNFα) [143] - or signalling molecules - sphingosine-1-phosphate, produced by sphingosine kinase 1 
(Sphk1), and S1P3 receptor, a G protein-coupled receptor enriched in astrocytes [144]. Similarly, the effect of 
nonsteroidal anti-inflammatory drugs was examined [145]. Results from these manipulations confirmed a 
modest improvement in lifespan and disease features in the SD mouse; overall inflammation appears to be a net 
contributor to the adverse effects of the primary neurodegenerative process in GM2 gangliosidosis. 
 
Neuronal death and degeneration 
Investigations of neuronal death in GM2 gangliosidoses by Huang [146] and Wada et al. identified many 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) positive cells in human and murine 
brains, considered a signature of apoptotic demise [140]. However, Sargeant and colleagues after studying the 
SD mouse brain found no extensive TUNEL-positive neurones. Instead, only the ventroposterior medial and 
ventroposterior lateral (VPM/VPL) nuclei of the thalamus showed prominent staining, and as expected for a 
progressive neurodegenerative disease, neuronal numbers decreased with age at these sites, accompanied by 
increases in activated microglia (Fig. 2). In addition, neuronal counts were taken from a number of other 
structures, and comparable loss of density was identiﬁed.  Among those analysed, only the lateral vestibular 
nucleus of the brainstem showed abundant cell loss; small but statistically signiﬁcant depletion of cells was 
detected in the ventral spinal cord [147]. Although neuronal loss might not be universal in the SD mouse at its 
humane end-point, neuronal dysfunction, as detected by silver staining, is widespread and demonstrable from a 
young age before disease signs are apparent [116] (Fig. 2). Of note, in human GM2 gangliosidosis, the amount 
of neuronal loss at the time of death is reported to vary considerably between cases but is more evident and 
widespread than in the Sandhoff mouse [104, 134]. The implication from these studies is that neuronal 
dysfunction, and not necessarily extensive cell depletion, is sufficient to cause the protean disease 
manifestations that characterize GM2 gangliosidosis. 
 
Neuroimaging 
Magnetic resonance imaging (MRI) of infantile GM2 gangliosidosis typically shows extensive T2-
weighted hyperintensities in cerebral white matter, basal ganglia, thalamus, pyramidal tract and cerebellum. 
Proton MR spectroscopy, which can be viewed as a non-invasive assay of brain metabolism, has shown that 
almost all brain regions have reduced MR signals due to  N-acetylaspartate and N-acetylaspartylglutamate 
(tNAA), with signals suggesting increased abundance of myo-inositol in white and gray matter. The 
concentration of choline-containing compounds generally remains unchanged, while creatine and the energy-
rich phosphocreatine appear to be present at increased abundance in cerebral white matter but markedly reduced 
in basal ganglia [148]. 
NAA localises almost exclusively to neurones and their processes [149], and its reduced abundance is 
associated with neuronal/axonal loss. Experimental and clinical studies suggest that diminished tissue 
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concentrations of NAA might indicate damage and neuronal dysfunction, rather than frank cell loss [150, 151]. 
Phosphorylcholine and glycerol phosphorylcholine appear to reflect membrane turnover. Phosphocreatine and 
creatine act as reserves for high-energy phosphates in the cytosol of neurons and glia [152]. Myo-inositol is a 
glial marker, predominantly found in astrocytes [153].  
Wilken and co-workers identified a novel MR spectroscopic signal in the brain of an infant with 
Sandhoff dissease: this was presumed to be N-acetylhexosamine. While this signal was more prominent in white 
matter, it was also present in the thalamic nuclei [154]. Of interest, the newly identified MR signal was also 
detected in the SD mouse brain.  High-performance liquid chromatography and mass spectrometry of mouse 
brain extracts identified N-acetylhexosamine-containing oligosaccharides as the most likely candidate for the 
new resonance signal - measurable in pre-symptomatic mice, and increasing in abundance over time as the 
disease progressed [155]. In summary, the pathology of infantile GM2 gangliosidosis as defined by 
neuroimaging is characterised by loss and/or dysfunction of neurones, demyelination and gliosis, and 
corresponds with the findings  reported in serial studies using conventional histological staining methods for 
examining neuropathogical changes in this disease. 
In contrast to the infantile forms of GM2, the only consistent abnormality noticed by MRI in late-onset 
patients is cerebellar atrophy and often hypodensity of the thalamus.  MR spectroscopy has been reported in one 
patient by Jamrozik et al. who identified a lower ratio for N-acetyl aspartate/creatine in cerebellum, lenticular 
nucleus and thalamus, and an increased ratio for myo-inositol/creatine in the cerebellum. Fluorodeoxyglucose 
positron emission tomography carried out in the same patient revealed diminished glucose metabolism in 
cerebellum, and in temporal and occipital lobes [156]. Inglese and colleagues investigated nine patients by MR 
spectroscopy and found the cerebellum to be markedly abnormal; however, their study also concluded that 
neuronal injury is diffuse [157]. 
Refinements in the resolution and advancing technology of clinical neuroimaging with increased 
sensitivity and scope, offer opportunities for non-invasive monitoring of disease progression and therapeutic 
efficacy in several neuropathic lysosomal diseases and may ultimately prove to be sufficiently responsive to 
metabolic changes in a manner that will contribute usefully to the clinical assessment of potential therapies. 
 
THERAPEUTIC MODALITIES FOR GM2 GANGLIOSIDOSIS  
Enzyme replacement therapy and cell transplantation 
With extraordinary prescience in 1964, de Duve foresaw the treatment of storage diseases by enzymatic 
supplementation [158]; the concept of inborn lysosomal storage diseases was proposed contemporaneously by  
HG Hers, who had identified the enzymatic deficiency of acid maltase in the glycogen storage disorder, Pompe 
disease [159]. Understanding of the underlying biology and methodology to implement enzyme supplementation 
came from studies in the laboratory of Elizabeth Neufeld. In their pioneering experiments, fibroblasts from MPS 
I (Hurler syndrome) and MPS II (Hunter syndrome) patients mutually complemented each other resulting in 
biochemical correction, leading them to conclude and later confirm, that functional complementation was due to 
the exchange of missing gene products or ‘corrective factors’ between the two fibroblast populations in culture 
[160-162]. The first and still the most successful treatment of any LSD by enzymatic supplementation is for type 
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I Gaucher disease; developed by Brady and co-workers over a period of almost 25 years and targeted to the 
diseased macrophage population via the avid mannose receptor[163]. Now known commercially as enzyme 
replacement therapy (ERT) this approach has also been developed for other LSDs with a prominent systemic 
phenotype, such as MPS I, Fabry disease, Pompe disease, MPS VI and MPS II. 
Desnick and colleagues in the 1970s, injected purified HEX A intravenously in an infant with Sandhoff 
disease; there was no clinical benefit. HEX A was present in the liver, but not in the cerebrospinal fluid or brain 
parenchyma [164, 165]. Even when purified HEX A was injected directly into the cerebrospinal fluid, clinical 
outcomes were equally disappointing [166]. Recently, Tsuji et al. infused recombinant HEX A intraventricularly 
into the SD mouse brain. Their isozyme was produced in the methylotrophic yeast strain Ogataea minuta, 
resulting in a protein with a high content in mannose 6-phosphate (M6P)-type-N-glycan. Outcomes from this 
intervention showed a modest salutary effect [167]. Although there are ongoing clinical trials of enzyme therapy 
for some neuropathic LSDs - Metachromatic Leukodystrophy, IDEAMLD phase I/II clinical trial 
(NCT01510028) - it is unlikely that ERT will ever be a definitive treatment for GM2 gangliosidosis. This is 
because of limited enzyme spread to the neuraxis, and the need for repeated and frequent applications. However, 
recently enzyme augmentation has had one striking clinical success that also represents a potential proof of 
concept for rescue of an acute neurodegenerative lysosomal disease by enzymatic complementation. Recent 
outcomes from a clinical trial of repeated intraventricular infusions of recombinant human tripeptidyl peptidase 
1 were shown to slow the loss of walking ability in symptomatic children aged 3 years and older who were 
affected by late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) which is caused by genetic deficiency of 
this lysosomal enzyme. This has led to the approval of the commercial enzyme developed by the Biomarin 
company (cerliponase alfa) as Brineura by the US Food and Drug Administration, in 2017. The protein is 
administered at doses of 300 mg over a period of 4-5 hours every two weeks and met the predefined criteria for 
safety and efficacy of this open-label study involving 22 patients with NCL2 compared with 42 untreated 
historical control patients [168]. 
Bone marrow transplantation is a cell-based method of delivering corrective enzyme to the brain. The 
aim is to persuade graft-derived monocytes to enter the host brain, secrete normal enzyme and cross-correct 
resident enzyme-deficient cells in a timely manner. Human patients have not benefited from this approach [169], 
but when the SD mouse was transplanted, survival was improved and disease manifestations progressed more 
slowly. Of note, however, no neurones were found to have detectable enzyme activity, nor was the amount of 
storage reduced. The authors attributed the beneficial effect to suppression of the innate inflammatory response 
by the graft [170]. Experimental evidence suggests that secretion of lysosomal enzymes by monocytes and other 
myeloid cells is protein- and species-specific.  For example, unlike the well-secreted feline α-mannosidase or β-
galactosidase, β-hexosaminidase is less abundant in the medium of cultured microglia [171, 172], and in line 
with these findings, bone marrow transplantation in human α-mannosidosis has been reported to be beneficial 
[173]. When delivered early to patients with MPS I, haematopoietic stem cell transplantation improves 
cognition and lifespan [174], but in the closely related disease MPS IIIA (mucopolysaccharidosis type IIIA or 
Sanfilippo type A), the same treatment extends life without neurological improvement [175]. Reports that the 
amount of enzyme produced by the graft impacts therapeutic outcomes, ‘more is better’, led Langford-Smith 
and colleagues to test this idea in the murine model of MPS IIIA. Enzyme augmentation resulted in a significant 
increase in lifespan and improved phenotype [176]  
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Should donor-derived myeloid cells be endowed will the ability to produce and secrete large quantities of 
HEX A by genetic manipulation, it is conceivable that cell transplantation might become a treatment option for 
GM2 gangliosidosis. Over recent years, better protocols for the management and prevention of graft-versus-host 
disease and improved survival from the myeloablative regimens used in the pre-engraftment conditioning, has 
encouraged clinical exploration of this stratagem in otherwise severe lysosomal diseases with neurological 
manifestations. 
 
Substrate reduction therapy 
Norman Radin was the first to propose reducing the burden of accumulated substrate in disorders such as 
storage diseases, by partially inhibiting the substrate-specific synthase. For this approach to succeed, significant 
residual or supplemented hydrolase activity is required. The rational is to balance the rate of substrate synthesis 
with that of diminished enzymatic degradative power [177]. Eliglustat tartrate (Genz-112638) is a synthetic 
analogue of glucosylceramide, a potent and specific inhibitor of glucosylceramide synthase (UDP-glucose: N-
acylsphingosine transferase), that has proved to be effective and safe in patients with non-neuronopathic 
Gaucher disease [178-181]. Because glucosylceramide is the first committed step in the biosynthesis of 
glycosphingolidpids, including GM2 ganglioside, inhibitors of glucosylceramide could be used, in principle, to 
treat GM2 gangliosidosis, provided they cross the blood-brain barrier. Unfortunately, a characteristic not 
attributable to eliglustat, but its congener venglustat, which does traverse the blood-brain barrier and unlike 
eliglustat  is not a substrate for the P-glycoprotein tranporter, is currently undergoing trials in type 3 (chronic 
neuropathic) Gaucher disease, Fabry disease and in patients with Parkinson disease who are heterozygous 
carriers of pathological mutation in the human GBA1 gene. 
Miglustat, the iminosugar N-butyldeoxynojirimycin, belongs to a different class of inhibitors of 
glucosylceramide synthase [182]. About 20% of the plasma concentrations of the drug have been found in 
human CSF after dosing, suggesting that it can to some extent cross the blood-brain barrier. The drug and is 
licenced as a second-line agent for the treatment of type 1 Gaucher disease [183], and as the only approved 
agent (in European patients) with  the neurodegenerative disorder Niemann-Pick type C [184]. While miglustat 
increased lifespan and improved clinical features in the SD mouse [185], in a clinical trial of late-onset TSD 
patients, the drug did not meet its efficacy endpoint target [186, 187]. Despite the disappointments, the search 
for inhibitors to reduce accumulating substrates in LSDs, and indeed in other diseases, is an active field of 
scientific endeavour. As exemplified by eliglustat, currently approved as Cerdelga, and a first-line therapy in 
type 1 Gaucher disease, with efficacy comparable to enzyme therapy in non-neuronopathic Gaucher disease, 
substrate reduction therapy by means of orally active small molecules, has therapeutic advantages. In the further 
development of this field, substrate reduction therapy for some sphingolipid disorders may prove to be of 
particular therapeutic value if used in combination with therapies that complement the lysosomal degradative 
function that is compromised in a given disease.   
 
Enzyme enhancing therapy  
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As pointed out above, most disease-causing missense mutations in GM2 gangliosidosis and in other 
LSDs, do not localise to the active site, but often cause instability of the native folded protein; targeted by the 
cellular quality control systems they are degraded before they can reach the lysosome. Strategies to reduce their 
degradation include the use of molecules that bind and stabilise the enzyme - chaperones - and in doing so 
protect it from degradation. Paradoxically, the most commonly used pharmacological chaperones are enzyme-
specific competitive inhibitors [188]. An altogether different approach is to tamper with the ERAD system to 
either prevent the faulty protein being recognised in the first instance, or by enhancing the function of 
endogenous chaperones [82]. 
Pharmacological chaperones that have shown some in vitro findings which may offer promise for some 
late-onset forms of lysosomal diseases including Krabbe [189], GM1gangliosidosis [190], Fabry disease [191], 
Gaucher disease[192], and GM2 gangliosidosis [193]. A  clinical trial with  the Hex A inhibitor pyrimethamine 
has taken placed, and although therapeutic outcomes were not fully assessed because of the short evaluation 
period, leukocyte Hex A activity was increased up to a 4-fold in some patients [194]. However, no clinical 
benefit has yet been reported. 
Kirkegaard and colleagues showed improved outcomes for animal models of several LSDs, including 
GM2 gangliosidosis, when the heat shock protein 70 (HSP70), an ER endogenous chaperone [195], was 
augmented in vivo. Intravenous or intraperitoneal injections of recombinant HSP70, or oral administration of its 
co-inducer, arimoclomol, both of which penetrate the brain, allowed for reduced cellular pathology and 
increased lifespan. In addition to its role as a chaperon of mutant proteins, HSP70 protects against 
permeabilization of lysosomes, which is another potential adverse pathological consequence of disturbed 
lysosomal physiology. Thus, HSP70 might constitute a supportive option with simultaneous effects on several 
mechanisms of disease [196]. Despite the scientific interest in enzyme enhancers, at the time of writing few if 
any of these enhancers have been rigorously tested in clinical trials, or indeed in authentic animal models of 
lysosomal diseases in which significant amounts of residual mutant enzyme are present. 
 
Gene therapy   
The once-in-a-life-time and definitive therapeutic intervention that gene therapy - the targeted 
manipulation of the genetic code - promises to deliver has long been awaited, and is particularly pressing for 
lysosomal diseases such as GM2 gangliosidosis, in which neurodegeneration is prominent. 
Many neuropathic LSDs have characteristics ideally suited to this treatment modality. They are caused 
by defects in single genes whose products are naturally secreted – a property that can readily be exploited. 
Transduction of relatively few cells can supply sufficient corrective enzyme to complement the deficiency in a 
large volume of tissue, and abundant enzyme can apparently be synthesised and secreted without cytotoxic 
effects. Moreover, as known from the pseudo-deficiencies - healthy individuals with very low amounts of active 
protein – estimated to be about 10% of normal activity is all that is needed to avoid disease. Currently, the 
greatest challenge to the successful treatment of these conditions is in the safe delivery of the corrective gene to 
the sites where is needed and in a timely fashion. This is because often the entire nervous system, made up of 
many complex domains and connections, is implicated in the degenerative process, and because the lysosomal 
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disease, long established in the nervous system, is almost invariably diagnosed after the onset of symptoms. 
Notwithstanding the difficulties outlined above, the management of these disorders, with all their idiosyncrasies, 
has never been so promising. There is genuine interest, focused research and investment into rare diseases by 
industry and academia. Unprecedented progress has been made in the last few years towards fulfilling the 
ultimate goal, with impressive examples of disease rescue in authentic animal models and scientific discoveries 
likely ultimately to enable present technical problems to be circumvented. 
Among viral vectors, recombinant Adeno-associated viruses (rAAV) have shown great potential for 
treating a variety of diseases, and have become the delivery vector of choice for the nervous system because 
most serotypes preferentially transduce neurons after intraparenchymal injection.  Wild type AAVs are small, 
20-25 nm in diameter, non-enveloped single-stranded DNA viruses of the Parvoviridae family. Unlike 
oncoretroviral and lentiviral vectors, their genome remains, to a large extent, episomal in the transduced cell, 
reducing the probability of insertional mutagenesis. For replication and gene expression, AAVs require a helper 
virus. Although they infect humans, integrating at a specific site in human chromosome 19, they are not 
associated with clinical disease [197], this feature is not preserved in recombinant AAVs. Many strains have 
been isolated from humans and primates, differing in cellular tropism and immunological properties [198, 199]. 
The 4.7 kb AAV genome is flanked by two inverted terminal repeats that contain the origin of replication, 
packaging and integration signals. Transgene-expressing rAAVs retain only the two inverted terminal repeats 
from their viral genome. Because rAAV could only be made in a small scale for many years, their use was 
restricted, but recent developments in their manufacture has permitted production in sufficiently large quantities 
for clinical applications [200]. rAAVs have been used in more than 100 clinical trials, a testament to their 
popularity, which has been attained as a result of their widespread tropism, capacity for inducing sustained gene 
expression in dividing and non-dividing cells and their safety record. 
Guidotti and colleagues carried out one of the earliest experimental gene transfer procedures in an 
animal model of GM2 gangliosidosis. Adenoviral vectors, encoding human α- and β-subunits of β-
hexosaminidase, were administered intravenously to TSD mice. This led to abundant expression of Hex A in 
serum and peripheral tissues, but was shown to be conditional upon both subunits being co-injected; α-subunit 
alone resulted in very low restoration of Hex A activity. As expected, neither vector nor β-hexosaminidase were 
able to cross the blood-brain barrier, but critically the study underscored the importance of co-expressing both 
hexosaminidase subunits, suggesting that if only one subunit is overexpressed the other becomes limiting [201]. 
Surprisingly, when Martino et al. infused non-replicating Herpes simplex vectors encoding human α-subunit 
alone directly into the internal capsule of TSD mice, they achieved distribution of Hex A and GM2 clearance 
throughout the brain, although not in the spinal cord [202]. Remarkable as these results are, the TSD mouse does 
not develop a clinical disease, and long-term efficacy was not reported, perhaps because the vector could not 
sustain extended transgene expression. 
Encouraged by positive outcomes in animal models of other LSDs after gene transfer mediated by 
rAAV delivery, the authors of this review investigated the corrective power of this approach in the SD mouse. 
In marked contradistinction to the TSD model, murine SD - a knockout of the β-subunit of β-hexosaminidase - 
displays a progressive neurodegenerative disease. It closely recapitulates the human disease biochemically and 
pathologically and has neurological effects which in many ways mirror those observed in affected children. The 
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SD mouse appears indistinguishable from wild type or heterozygous littermates at birth, but by the age of 3 
months motor abnormalities are noticeable, and soon after, the animal enters a phase of rapid decline with death 
occurring 1-2 months later. Stereotypic manifestations, which increase in severity as the disease progresses, 
include tremor, ataxia, rigidity, and spasticity [99]. Young adult SD mice, age 4-5 weeks, were injected with 
rAAV, serotypes 2/2 or 2/1 at intracranial sites. Monocistronic vectors expressing human α- (rAAV-α) or β-
subunits (rAAV-β) were infused singly or in combination at one or multiple sites in the brain parenchyma (Fig. 
3). Rescue of the phenotype was achieved when the animals were given the combination treatment (rAAV-α + 
rAAV-β) or rAAV-β alone, but as expected, not when only rAAV-α was supplied. Mice were still alive and 
apparently healthy at the age of 2 years, the predefined end-point of the experiment. Concomitant with the 
phenotypic rescue, pathological features, namely, storage, inflammation and neurodegeneration, were reduced 
or undetectable in the brain and spinal cord. We have evidence indicating that the unprecedented outcome is the 
result of extensive spread of vector and protein through several routes: diffusion, axonal, perivascular and 
cerebrospinal fluid transport. We reported significant therapeutic benefit accrued after a single injection into one 
anatomical site. However, multiple injections improved outcomes, and are necessary for neuraxis-wide 
distribution of enzyme [203, 204] (Fig. 3). We present here unpublished data, showing salutary effects in SD 
mice injected with the combination treatment (rAAV-α + rAAV-β) into the cerebrospinal fluid; animals aged 4-
5 weeks were infused through one lateral ventricle. Abundant formation of HEX A at distant sites, such as the 
spinal cord was demonstrated, life was extended and classical pathological features reduced (Fig. 4). 
We explain the positive effects resulting from rAAV-β only interventions by the observed production 
of copious amounts of isozyme HEX B, and not from the abundant formation of interspecies hybrid HEX A. 
This notion is supported by separation of the different isozymes by ion-exchange chromatography and their 
identification using isozyme-selective artificial substrates, as well as cellulose-acetate electrophoresis of brain 
extracts [204]. In the presence of Hex B, the aforementioned biochemical bypass, mediated by an efficient 
apparently species-specific sialidase (Neu3) as occurs in the TSD mouse [101], would presumably operate also 
in the SD mouse transduced with rAAV-β alone. In humans, with no such endogenous sialidase, co-expression 
of both subunits by the simultaneous injection of rAAV-α and rAAV-β is an absolute requirement to maximise 
treatment efficacy. Because each of the recombinant viruses only drive expression of one of the subunits, 
simultaneous cellular infection by the two vectors must occur in order to form heterodimeric HEX A. This we 
confirmed by mRNA in situ hybridization of transduced brain sections; dual labelling of the two mRNA 
subunits was detected in individual cell nuclei, albeit at different ratios (Fig. 3).  
As with any treatment, early intervention is predicted to improve outcomes, particularly for 
neurodegenerative diseases, because of the limited regenerative capability of the nervous system. It is unknown 
how narrow the window of opportunity to treat GM2 gangiosidosis really is; whether we can prevent, halt or 
even reverse the disease or indeed when the point of no return has been reached. Using the SD mouse as a 
paradigm, we injected the animals with a combination of rAAV-α and rAAV-β at different ages and took them 
to their humane end points. These studies showed improved survival only when the animals were treated before 
disease signs were  apparent or during their early manifestation, but not if treatment was initiated during the 
peri-symptomatic/symptomatic phase of the illness. A remarkable finding from these experiments was that 
despite the elapse of the therapeutic window so that the treatment had no beneficial effects on survival, abundant 
and widespread expression of β-hexosaminidase, which abrogated pathological features such as storage and 
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neuroinflammation, had still occurred. We concluded from these experiments that regardless of resolution of the 
cardinal pathological features mediated by gene transfer, a point is reached when functional deterioration and 
death are not preventable in GM2 gangliosidosis [116]). 
Therapeutic outcomes in the SD mouse after intracranial injections with rAAV prompted us to seek 
reproducibility of the results in animal species with larger and more complex brains, as the most important next 
phase towards human clinical trials. Bearing in mind that the mouse, cat and sheep’s brain is about 1/1000, 1/13 
and 1/3 the size of a new-born human brain respectively, the cat represents an intermediate and appropriate 
candidate to test our gene transfer stratagem within a research environment. We approached Prof Henry J Baker 
(based at the Scott-Ritchey Research Centre, College of Veterinary Medicine, Auburn University) who with 
stubborn determination had maintained naturally occurring cat models of GM2 gangliosidosis for decades, 
understanding their importance to study mechanisms of disease and to test novel therapies, and a fruitful 
scientific collaboration was established. 
The lifespan of normal cats is 12-14 years, while that of the SD cat is approximately 6 months. Onset of 
disease manifestations occurs at age 4-7 weeks, which include hypermetria, tremor, ataxia, paresis and seizures 
[205, 206]. Mutant cats were treated presymptomatically with a variety of rAAV serotypes. Monocistronic 
vectors expressing feline-specific α- and β-subunits were co-infused into either the thalamus and deep cerebellar 
nuclei [207, 208] or thalamus and lateral ventricle [209-211]. The different gene transfer modalities resulted in 
enzymatic activities above normal levels throughout the neuraxis, with concomitant reduction of storage 
compounds, amelioration of clinical signs and extension of life. Reproducibility of our mouse results in the 
larger and complex cat brain lends further support and justifies initiation of human clinical trials in the near 
future to treat these devastating and fatal diseases. 
The need to co-express the two β-hexosaminidase subunits and the failure of single bicistronic rAAV 
vectors in co-synthesizing both peptides appropriately adds undesirable complexity and expense to the potential 
use of this treatment modality in the clinic; hitherto, only co-infusion of monocistronic vectors has been 
successful at generating therapeutic amounts of HEX A in vivo. However, a recent and exciting development 
might circumvent this difficulty. Tropak and colleagues reported the generation of a hybrid subunit they call μ 
that combines features of the two native forms. The μ-subunit contains the α-subunit active site, the stable β-
subunit interphase, and a unique area in each of the subunits mandatory for interaction with the GM2 activator 
protein. This elegant “Frankenstein” approach to the problem results in homodimerization of μ-subunits and 
formation of the active isozyme named HEX M. Furthermore, when they intracranially injected 4-month old 
TSD mice with self-complementary AAV9 (scAAV9) expressing HEXM, there was a reduction in brain 
ganglioside and its clearance was comparable to outcomes observed in animals injected with scAAV9 
expressing HEXA. The study was extended to SD mice injected intravenously during the neonatal period with 
scAAV9-HEXM. These animals showed decreased brain ganglioside despite the presence of low levels of HEX 
M, which the authors speculated was the result of poor transfer of vector from the circulation into brain 
structures [212]. In a different publication, the same group demonstrates that clearance of pathological storage is 
accompanied by an increased in lifespan and recovery of motor function in these animals [213]. These results 
are quite remarkable, but there remains a nagging concern about the functionality and safety of this 
“Frankenstein” creation for use in human patients; in particular the possibility that it may prove to be strongly 
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immunogenic. It is thus imperative that its long-term efficacy and safety record is comprehensively tested in 
larger animals. 
The discovery that some AAV serotypes can cross the blood-brain barrier when injected intravenously, 
spreading widely throughout the neuraxis, constitutes a major leap forward for the treatment of 
neurodegenerative disorders. Among these, AAV9 [214], AAVrh8 and AAVrh10 [215, 216] have been 
extensively tested. Walia and co-workers intravenously injected rAAV9 expressing murine hexb into neonates 
and adult SD mice, extending life and reducing storage and inflammation [217]. The major concern raised by 
the study was the development of tumours in liver and lung in older mice. Others have reported similar accounts 
when rAAVs are injected systemically at a high dose. With the development of tumours only revealed in 
animals kept alive for prolonged periods, a cautious approach is warranted [218-220]. Undoubtedly, these initial 
aspect are disappointing, but a huge effort is being invested in generating viruses with improved specific 
targeting of cell types. Directed evolution of rAAV is an approach to select viruses that imitates natural 
evolution under selective pressure and experimental results with these viruses are encouraging [221-224]. 
 
CONCLUDING REMARKS 
The story of Tay-Sachs disease, the discovery of its complex genetics, biochemical components and their 
function is inextricably linked to some of the most important scientific discoveries, technical innovations and 
historical events of the 20th century. The next phase in the narrative of this rare but devastating disease must 
surely be the dawn of effective treatments. Of the stratagems outlined above, with its substantial therapeutic 
benefit convincingly reported in authentic living models, and because it aims definitively to correct the initiating 
cause of the disease, the most attractive hitherto appears to be gene transfer. However, for certain clinical forms 
of Tay-Sachs and its related diseases, combinatorial approaches may also be considered: for example, the use of 
substrate biosynthesis inhibitors and agents that simultaneously target distinct pathological mechanisms of 
disease may also offer much-needed clinical benefit. 
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LEGENDS TO FIGURES 
 
Fig. (1). Catabolism of GM2 ganglioside by the β-hexosaminidase system and transport to the lysosome. 
GM2 ganglioside is hydrolysed in vivo in the lysosome by the concerted action of the isozyme Hex A and GM2 
activator protein. Hex A is a heterodimer of the α- and β-subunits of β-hexosaminidase, and encoded by HEXA 
and HEXB, which localize to human chromosomes 15 and 5, respectively. Hex B and Hex S are homodimers of 
the β- and α-subunits. Only dimeric forms of Hex can hydrolyse specific natural and artificial substrates. 
Mutations in HEXA, HEXB and GM2A cause Tay-Sachs disease, Sandhoff disease and the GM2 activator 
protein deficiency respectively, also known as variants B, 0, and AB on the basis of the residual β-
hexosaminidase isozyme activities in affected individuals. In a similar manner to other lysosomal hydrolases, 
Hex can travel to the lysosome directly (1, a) or indirectly (2, b). The latter route, known as the 
secretion/recapture mechanism, can be exploited for therapeutic applications; whereby the enzyme is secreted 
into the extracellular space and taken up by the same (d) or neighbouring cells, such as the axons of neurones 
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(c). The enzyme is transported in a retrograde manner to other parts of the cell thus correcting the enzymatic 
defect. Endoplasmic reticulum (ER); lysosome (L); mitochondria (M).  
 
Fig. (2). Pathologic features of GM2 gangliosidosis. The most notable feature is the presence of grossly 
enlarged neurones throughout the nervous system, due to the presence of membranous cytoplasmic bodies 
(MCBs *), which are abnormal lysosomes, easily revealed by electron microscopy (EM). MCBs stain with 
Periodic acid-Schiff reagent (PAS) and antibodies against GM2 ganglioside.  Activation and expansion of 
microglia is evident in many areas and revealed by staining for cell markers such as CD68, prominent here in 
the VPM/VPL nuclei of the thalamus. Neurodegeneration is detectable by silver staining, abundant in neuronal 
cell bodies and axons such as those of the internal capsule (IC). Impaired autophagy in neurones is shown by co-
staining proteins p62 and ubiquitin. All sections are from Sandhoff mouse brain. Fields CA1 (CA1) and CA3 
(CA3) of hippocampus (Hipp); ﬁmbria (ﬁ); granular layer of the dentate gyrus (GrDG); internal capsule (IC); 
nucleus (N); ventroposterior medial (VPM) and lateral (VPL or LP) thalamic nuclei; primary somatosensory 
cortex (S1). 
 
Fig. (3). Brain parenchymal gene transfer of rAAV monocistronic vectors rescues the Sandhoff mouse 
phenotype. Infusion of rAAVs coding for human α- (hhex α) and β-subunits (hhex β) of β-hexosaminidase 
leads to distribution of Hex enzyme (red precipitate) throughout the entire neuraxis, seen here in a mutant 
animal aged 2 years. Dual mRNA in situ hybridization with probes specific for the α- and β-subunits detects the 
presence of both mRNAs in transduced neurones, a pre-requisite for the formation of abundant amounts of Hex 
A. Consequently, storage material is cleared or prevented as seen here in the spinal cord of a 2-year old mutant 
Sandhoff mouse. Central canal (cc); grey matter (gm); white matter (wm); CAG promoter is a composite 
promoter of the CMV enhancer, the chicken beta actin promoter, and the rabbit beta globin intron (CAGp); 
human immunodeficiency virus tat protein transduction domain (tat); woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE); inverted terminal repeat (ITR). 
 
Fig. (4). A single ventricular co-infusion of rAAVs into the Sandhoff brain rescues the mouse phenotype. 
Four-week old Sandhoff mice were injected into one of the brain lateral ventricles with rAAV2/1 coding for α- 
and β-subunits of β-hexosaminidase. The intervention increased survival with supranormal formation of all three 
Hex isozymes, which are distributed throughout the entire central nervous system. Fractionation of the isozymes 
was carried out on the brain contralateral injection side by ion exchange chromatography. Hex activities were 
detected with the artificial substrate 4-MUG (4-methylumbelliferyl-2-acetamido-2-deoxy-ß-D-glucopyranoside). 
